Cholestatic pruritus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:06:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cholestatic pruritus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-term Safety of Linerixibat for Treating Itchy Skin in Patients with Primary Biliary Cholangitis https://clinicaltrials.eu/trial/study-on-long-term-safety-of-linerixibat-for-treating-itchy-skin-in-patients-with-primary-biliary-cholangitis/ Wed, 29 Apr 2026 14:23:26 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-linerixibat-for-treating-itchy-skin-in-patients-with-primary-biliary-cholangitis/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called linerixibat for treating a condition known as cholestatic pruritus in people with Primary Biliary Cholangitis (PBC). Cholestatic pruritus is a type of itching that occurs when there is a problem with bile flow in the liver, and PBC is a chronic disease that slowly destroys the bile ducts in the liver. The medication being tested, linerixibat, is taken in the form of tablets.

The purpose of the study is to evaluate how safe and tolerable linerixibat is when used over a long period. Participants in the study will take linerixibat orally, and the study will monitor them for any side effects or adverse events. The study will involve regular check-ups at various intervals, such as weekly, monthly, and every few months, to ensure the safety of the participants and to gather data on how the medication affects them over time.

Throughout the study, participants will be assessed for changes in their health, including any improvements or worsening of their symptoms. The study will also look at how the medication affects participants’ quality of life, including aspects like sleep and fatigue. This trial aims to provide valuable information on the long-term use of linerixibat for individuals with PBC who experience cholestatic pruritus.

]]> Study on Maralixibat Chloride for Treating Itchy Skin in Patients with Cholestatic Pruritus https://clinicaltrials.eu/trial/study-on-maralixibat-chloride-for-treating-itchy-skin-in-patients-with-cholestatic-pruritus/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-on-maralixibat-chloride-for-treating-itchy-skin-in-patients-with-cholestatic-pruritus/ This clinical trial is focused on studying the effects of a treatment for cholestatic pruritus, a condition characterized by severe itching due to liver problems. The treatment being tested is called Maralixibat chloride, which is taken as an oral solution. This medication works as an ileal bile acid transporter (IBAT) inhibitor, which means it helps to reduce the amount of bile acids in the body that can cause itching.

The purpose of the study is to evaluate how effective Maralixibat chloride is compared to a placebo in reducing the severity of itching in participants with cholestatic pruritus. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for a period of 40 weeks, during which participants will take the oral solution and attend regular study visits to monitor their condition and any changes in their symptoms.

Throughout the study, participants will be asked to report on their itching symptoms using a tool called the Itch-Reported Outcome (ItchRO), which helps to measure the severity of their itching. The study aims to see if there is a significant improvement in the itching symptoms of those taking Maralixibat chloride compared to those taking the placebo. This research is important for finding better ways to manage and treat the discomfort associated with cholestatic pruritus.

]]>